McKesson Corporation (MCK)

McKesson's price sits above every major trend line it tracks, even after dipping about 4% over the past week.

What is going on right now?

The stock slipped roughly 3% in the last day and nearly 4% over the past week, on lighter-than-usual trading activity. It still sits above where it was trading one, two, and six months ago.

How is the business itself doing?

McKesson is a giant middleman for pharmaceuticals, moving drugs from makers to pharmacies. Sales grew about 8% recently, but the company's earnings fell roughly 18%, a reminder that its slice on each dollar passing through is very thin, around one cent of profit per dollar of revenue.

What stands out?

The company generates $6.8 billion in cash from operations, which is large for a business with such slim margins. Its short-term bills slightly exceed what it has on hand to pay them, so that cash flow matters a lot.

What comes next?

McKesson's next earnings report is scheduled for November 4, 2026, and it will show whether the gap between growing sales and shrinking profits is narrowing or widening.